申请人:Ohta Toshiharu
公开号:US20080015215A1
公开(公告)日:2008-01-17
A compound represented by the general formula (1):
Q
1
-Q
2
-T
0
-N(R
1
)-Q
3
-N(R
2
)-T
1
-Q
4
(1)
wherein R
1
and R
2
are hydrogen atoms or the like; Q
1
is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q
2
is a single bond or the like; Q
3
is a group
in which Q
5
is an alkylene group having 1 to 8 carbon atoms, or the like; and T
0
and T
1
are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof.
The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.
化合物的普通式表示为(1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4(1),其中R1和R2是氢原子或类似物;Q1是饱和或不饱和的、5-或6-成员环烃基,可以被取代,或类似物;Q2是单键或类似物;Q3是其中Q5是1到8个碳原子的烷基或类似物的基团;T0和T1是羰基或类似物;其盐、溶剂化物或N-氧化物。该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布氏病、深静脉血栓形成、弥漫性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征(SIRS)、多器官功能障碍综合征(MODS)、体外循环期间的血栓形成或采血时的血液凝固。